Research Analysts Issue Forecasts for BMRN FY2025 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a research note issued on Friday, May 2nd. Cantor Fitzgerald analyst O. Brayer now forecasts that the biotechnology company will post earnings of $3.61 per share for the year, up from their prior forecast of $3.53. Cantor Fitzgerald currently has a “Overweight” rating and a $90.00 price target on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

Several other equities analysts have also recently weighed in on BMRN. The Goldman Sachs Group cut their price objective on BioMarin Pharmaceutical from $124.00 to $104.00 and set a “buy” rating on the stock in a report on Monday. StockNews.com raised shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. Oppenheimer raised BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 price target on the stock in a research note on Monday, February 24th. Royal Bank of Canada reiterated a “sector perform” rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Finally, Bank of America upped their price target on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $93.45.

BioMarin Pharmaceutical Price Performance

BMRN opened at $62.06 on Monday. The company has a fifty day simple moving average of $65.71 and a 200 day simple moving average of $65.66. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The stock has a market cap of $11.84 billion, a P/E ratio of 28.21, a P/E/G ratio of 0.61 and a beta of 0.27. BioMarin Pharmaceutical has a 12 month low of $52.93 and a 12 month high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating analysts’ consensus estimates of $0.54 by $0.18. The business had revenue of $747.31 million for the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%.

Insider Transactions at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 1,295 shares of BioMarin Pharmaceutical stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.52, for a total transaction of $92,618.40. Following the completion of the sale, the chief accounting officer now owns 16,955 shares of the company’s stock, valued at approximately $1,212,621.60. This trade represents a 7.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in BMRN. Norges Bank bought a new position in BioMarin Pharmaceutical during the 4th quarter worth $234,645,000. Capital Research Global Investors increased its position in shares of BioMarin Pharmaceutical by 23.8% in the fourth quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company’s stock worth $853,944,000 after purchasing an additional 2,496,817 shares during the period. Soleus Capital Management L.P. acquired a new position in BioMarin Pharmaceutical in the fourth quarter valued at about $65,822,000. Dodge & Cox lifted its position in BioMarin Pharmaceutical by 6.1% during the fourth quarter. Dodge & Cox now owns 14,746,235 shares of the biotechnology company’s stock worth $969,270,000 after purchasing an additional 847,917 shares during the period. Finally, AQR Capital Management LLC grew its stake in BioMarin Pharmaceutical by 114.5% during the fourth quarter. AQR Capital Management LLC now owns 1,283,599 shares of the biotechnology company’s stock worth $84,371,000 after buying an additional 685,099 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.